Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

GYRE Gyre Therapeutics PE ratio, current and historical analysis

The current price-to-earnings ratio for Gyre Therapeutics stock as of May 30, 2025 is 113.38. This is calculated based on the current EPS of $0.08 and the stock price of $9.07 per share.

GYRE PE ratio history

How has GYRE's PE ratio performed in the past

The average historical PE ratio of Gyre Therapeutics for the last nine years is 64.88. The current PE ratio of 113.38 is 75% above the historical average. In the past nine years, GYRE's PE ratio was at its highest in the Dec 2022 quarter at 197.8, when the stock price was $7.91 and the EPS was $0.04. The lowest value was in the Mar 2023 quarter, when it reached 0.44 with a price of $3.11 and an EPS of $6.98.

Today
113.38
Average
64.88
Median
46.6
Minimum
0.44
Maximum
197.8

Gyre Therapeutics PE ratio by year

Year PE ratio PE change Price EPS
2024 86.43 N/A $12.1 $0.14
2023 N/A N/A $25.69 -$1.41
2022 197.8 N/A $7.91 $0.04
2021 N/A N/A $13.71 -$43.05
2020 N/A N/A $94.65 -$43.95
2019 N/A N/A $102.15 -$69
2018 N/A N/A $118.35 -$40.2
2017 N/A N/A $204.6 -$111.75
2016 N/A N/A $146.25 -$326.25
2015 N/A N/A $704.25 -$749.85
2014 N/A N/A $4,142.25 -$4,047.75
2013 N/A N/A $6,536.25 -$6,140.25
2012 N/A N/A $6,898.5 -$330.75
2011 N/A N/A $8,772.75 -$425.25
2010 69.74 N/A $41,737.5 $598.5

Gyre Therapeutics PE ratio by quarter (TTM)

Year PE ratio PE change Price EPS
Mar 2025 96.5 11.65% $7.72 $0.08
Dec 2024 86.43 N/A $12.1 $0.14
Sep 2024 N/A N/A $12.54 -$1.4
Jun 2024 N/A N/A $11.93 -$1.35
Mar 2024 N/A N/A $17.48 -$1.36
Dec 2023 N/A N/A $25.69 -$1.41
Sep 2023 N/A N/A $7.23 -$15.13
Jun 2023 N/A N/A $5.27 -$17.59
Mar 2023 0.44 -99.78% $3.11 $6.98
Dec 2022 197.8 14,772.18% $7.91 $0.04
Sep 2022 1.33 N/A $7.56 $5.7
Jun 2022 N/A N/A $26.7 -$3.9
Mar 2022 N/A N/A $9.9 -$38.1
Dec 2021 N/A N/A $13.71 -$43.05
Sep 2021 N/A N/A $61.65 -$46.65

GYRE Price vs fair value

How does GYRE's price compare to its estimated fair value based on its growth

GYRE average PE ratio chart

What is the average PE ratio of GYRE for the past years

The current PE ratio of GYRE is above the 3, 5 and 10-year historical averages.

3-year avg
76.5
5-year avg
76.5
10-year avg
64.88
15-year avg
206.26

GYRE PE vs peers

What is GYRE's PE ratio compared to its peers
Stock name PE ratio Market cap
GYRE Gyre Therapeutics Inc 113.38 $850.38M
OLMA Olema Pharmaceuticals Inc N/A $361.26M
OMER Omeros Corp N/A $181.05M
VIVS VivoSim Labs Inc. N/A $2.62M
ORIC Oric Pharmaceuticals Inc N/A $580.79M
ORMP Oramed Pharmaceuticals Inc N/A $95.59M

Frequently asked questions

What is Gyre Therapeutics's PE ratio?

The price to earnings ratio for GYRE stock is 113.38 as of May 30, 2025.

What is the 3-year average PE ratio for Gyre Therapeutics (GYRE)?

Over the last 3 years, the average price to earnings ratio for GYRE stock is 76.5.

What is the 5-year average PE ratio for Gyre Therapeutics (GYRE)?

Over the last 5 years, the average price to earnings ratio for GYRE stock is 76.5.

What is the highest PE ratio for GYRE?

Over the last nine years, the quarterly PE ratio reached a historic high of 197.8 in the Dec 2022 quarter.

How does the current PE ratio for GYRE compare to its historical average?

The current price to earnings ratio of GYRE is 75% higher than the 9-year historical average.

Why is Gyre Therapeutics's PE ratio so high?

A company with a higher PE ratio may indicate that the market has higher growth expectations for the company's future earnings or profitability.

How is GYRE's PE ratio calculated (Gyre Therapeutics PE ratio formula)?

The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (May 30, 2025), Gyre Therapeutics's stock price is $9.07. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $0.08. Therefore, Gyre Therapeutics's P/E ratio for today is 113.38. PE RATIO(113.38) = STOCK PRICE($9.07) / TTM EPS($0.08)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.